Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain

Gut

Volumn 59, Issue 9, 2010, Pages 1236-1244

  Stange, D E ^a,b   Engel, F ^a   Longerich, T ^b   Koo, B K ^c   Koch, M ^b   Delhomme, N ^a   Aigner, M ^b   Toedt, G ^a   Schirmacher, P ^b   Lichter, P ^a   Weitz, J ^b   Radlwimmer, B ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ASCL2; UNCLASSIFIED DRUG; ASCL2 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; IGF2 PROTEIN, HUMAN; SOMATOMEDIN B;

ARTICLE; CHROMOSOME ABERRATION; CLUSTER ANALYSIS; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; BIOSYNTHESIS; CANCER STEM CELL; CHROMOSOME 11; COLORECTAL TUMOR; DNA MICROARRAY; GENETICS; GENOME; LIVER TUMOR; METABOLISM; PHENOTYPE; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENOME; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77956107307     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.195701     Document Type: Article

References (55)

1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119-52.
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
3. Biasco G, Derenzini E, Grazi G, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006;32:214-28.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Nadal C, Maurel J, Gascon P. Is there a genetic signature for liver metastasis in colorectal cancer? World J Gastroenterol 2007;13:5832-44.
7. Diep CB, Kleivi K, Ribeiro FR, et al. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 2006;45:31-41.
8. Cardoso J, Boer J, Morreau H, et al. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 2007;1775:103-37. (Pubitemid 44881195)
9. Hughes S, Williams RD, Webb E, et al. Meta-analysis and pooled re-analysis of copy number changes in colorectal cancer detected by comparative genomic hybridisation. Anticancer Res 2006;26:3439-44.
10. Yanagawa R, Furukawa Y, Tsunoda T, et al. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 2001;3:395-401.
11. Koehler A, Bataille F, Schmid C, et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 2004;204:65-74.
12. D'Arrigo A, Belluco C, Ambrosi A, et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 2005;115:256-62.
13. Koh KH, Rhee H, Kang HJ, et al. Differential gene expression profiles of metastases in paired primary and metastatic colorectal carcinomas. Oncology 2008;75:92-101.
14. Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-12.
15. Platzer P, Upender MB, Wilson K, et al. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002;62:1134-8.
16. Tsafrir D, Bacolod M, Selvanayagam Z, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006;66:2129-37.
17. Schlaeger C, Longerich T, Schiller C, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008;47:511-20.
18. Stange DE, Radlwimmer B, Schubert F, et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006;12:345-52.
19. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005;23:8853-62.
20. Hupe P, Stransky N, Thiery JP, et al. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20;3413-22. (Pubitemid 40136776)
21. Shimodaira H. An approximately unbiased test of phylogenetic tree selection. Syst Biol 2002;51:492-508. (Pubitemid 35180700)
22. Mehta KR, Nakao K, Zuraek MB, et al. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res 2005;11:1791-7.
23. Douglas EJ, Fiegler H, Rowan A, et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 2004;64:4817-25.
24. Jong K, Marchiori E, Meijer G, et al. Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics 2004;20:3636-7.
25. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
26. van der Flier LG, van Gijn ME, Hatzis P, et al. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009;136:903-12.
27. Van der Flier LG, Sabates-Bellver J, Oving I, et al. The Intestinal Wnt/TCF Signature. Gastroenterology 2007;132:628-32.
28. Leibovitz A, Stinson JC, McCombs WB 3rd, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976;36:4562-9.
29. Fijneman RJ, Carvalho B, Postma C, et al. Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer. Cancer Lett 2007;258:223-9. (Pubitemid 350101027)
30. Nakao K, Mehta KR, Fridlyand J, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 2004;25:1345-57.
31. Nakao M, Kawauchi S, Furuya T, et al. Identification of DNA copy number aberrations associated with metastases of colorectal cancer using array CGH profiles. Cancer Genet Cytogenet 2009;188:70-6.
32. Kim MY, Yim SH, Kwon MS, et al. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006;131:1913-24.
33. van der Flier LG, Haegebarth A, Stange DE, et al. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 2009;137:15-17.
34. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
35. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004;23:11-27.
36. Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002;123:1109-19.
37. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
38. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, et al. Gene expression in colorectal cancer. Cancer Res 2002;62:4352-63.
39. Kleivi K, Lind GE, Diep CB, et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer 2007;6:2.
40. Lin HM, Chatterjee A, Lin YH, et al. Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep 2007;17:1541-9.
41. Yamasaki M, Takemasa I, Komori T, et al. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol 2007;30:129-38.
42. Diep CB, Teixeira MR, Thorstensen L, et al. Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. Mol Cancer 2004;3:6.
43. Habermann JK, Paulsen U, Roblick UJ, et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007;46:10-26.
44. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:998-1003. (Pubitemid 12059094)
45. Cahill DP, Kinzler KW, Vogelstein B, et al. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
46. Carvalho B, Postma C, Mongera S, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009;58:79-89.
47. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
48. Heiskala K, Giles-Komar J, Heiskala M, et al. High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei. Virchows Arch 2006;448:295-300.
49. Metsis M, Cintra A, Solfrini V, et al. Molecular cloning of PEC-60 and expression of its mRNA and peptide in the gastrointestinal tract and immune system. J Biol Chem 1992;267:19829-32.
50. Li CK, Pender SL, Pickard KM, et al. Impaired immunity to intestinal bacterial infection in stromelysin-1 (matrix metalloproteinase-3)-deficient mice. J Immunol 2004;173:5171-9.
51. Oue N, Kuniyasu H, Noguchi T, et al. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 2007;72:371-80.
52. Jubb AM, Chalasani S, Frantz GD, et al. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 2006;25:3445-57.
53. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.
54. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A 2007;104:20926-31.
55. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307:1976-8.